At ASH 2025, Dr. Shannuo Li from the University of Utah, USA shares her perspective on emerging strategies for multi-target immune engagement, exploring the potential of simultaneously targeting BCMA, CD38, and GPRC5D to address therapeutic resistance in myeloma.
In this on-site interview, Dr. Li discusses why resistance remains a key challenge in current treatment approaches and how innovative molecular design and immune engagers may help shape the future of hematologic therapies.
Watch the full interview to learn how cutting-edge research is driving the next generation of immunotherapy.
